{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:50:32Z","timestamp":1788234632389,"version":"build-2803163510"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Wormwood (<jats:italic>Artemisia<\/jats:italic>) pollen is among the top 10 aeroallergens globally that cause allergic rhinitis and bronchial asthma. Allergen-specific immunotherapy (ASIT) is the gold standard for treating patients with allergic rhinitis, conjunctivitis, and asthma. A significant disadvantage of today\u2019s ASIT methods is the long duration of therapy and multiplicity of allergen administrations. The goal of this study was to undertake a pilot study in mice of a novel ultrashort vaccine immunotherapy regimen incorporating various adjuvants to assess its ability to treat allergic bronchial asthma caused by wormwood pollen.<\/jats:p><jats:p>We evaluated in a mouse model of wormwood pollen allergy candidates comprising recombinant Art v 1 wormwood pollen protein formulated with either newer (Advax, Advax-CpG, ISA-51) or more traditional [aluminum hydroxide, squalene water emulsion (SWE)] adjuvants administered by the intramuscular or subcutaneous route vs. intranasal administration of a mucosal vaccine formulation using chitosan-mannose nanoparticle entrapped with Art v 1 protein. The vaccine formulations were administered to previously wormwood pollen-sensitized animals, four times at weekly intervals. Desensitization was determined by measuring decreases in immunoglobulin E (IgE), cellular immunity, ear swelling test, and pathological changes in the lungs of animals after aeroallergen challenge. Art v 1 protein formulation with Advax, Advax-CpG, SWE, or ISA-51 adjuvants induced a significant decrease in both total and Art v 1-specific IgE with a concurrent increase in Art v 1-specific IgG compared to the positive control group. There was a shift in T-cell cytokine secretion toward a Th1 (Advax-CpG, ISA-51, and Advax) or a balanced Th1\/Th2 (SWE) pattern. Protection against lung inflammatory reaction after challenge was seen with ISA-51, Advax, and SWE Art v 1 formulations. Overall, the ISA-51-adjuvanted vaccine group induced the largest reduction of allergic ear swelling and protection against type 2 and non-type 2 lung inflammation in challenged animals. This pilot study shows the potential to develop an ultrashort ASIT regimen for wormwood pollen-induced bronchial asthma using appropriately adjuvanted recombinant Art v 1 protein. The data support further preclinical studies with the ultimate goal of advancing this therapy to human clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2022.828690","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T08:47:59Z","timestamp":1647334079000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of a Novel Adjuvanted Vaccine for Ultrashort Regimen Therapy of Artemisia Pollen-Induced Allergic Bronchial Asthma in a Mouse Model"],"prefix":"10.3389","volume":"13","author":[{"given":"Kairat","family":"Tabynov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meruert","family":"Babayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tair","family":"Nurpeisov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gleb","family":"Fomin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temirzhan","family":"Nurpeisov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulbossyn","family":"Saltabayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar","family":"Renu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourapura J.","family":"Renukaradhya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaissar","family":"Tabynov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40413-018-0187-2","article-title":"The Importance of Allergic Disease in Public Health: An iCAALL Statement","volume":"11","author":"S\u00e1nchez-Borges","year":"2018","journal-title":"World Allergy Organ J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 Update (in Collaboration With the World Health Organization, GA(2)LEN and AllerGen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201190061","article-title":"Fighting Allergies Beyond Symptoms: The European Declaration on Immunotherapy","volume":"41","author":"Akdis","year":"2011","journal-title":"Eur J Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)78276-6","article-title":"Prophylactic Inoculation Against Hay Fever","volume":"1","author":"Noon","year":"1911","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70271-4","article-title":"Allergen Immunotherapy: Therapeutic Vaccines for Allergic Diseases","volume":"102","author":"Bousquet","year":"1998","journal-title":"A WHO position paper. J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jaci.2010.11.030","article-title":"Mechanisms of Allergen-Specific Immunotherapy","volume":"127","author":"Akdis","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.118891","article-title":"Aria Workshop Group; World Health Rganization. Allergic Rhinitis and Its Impact on Asthma","volume":"108","author":"Bousquet","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"B8","article-title":"Adverse Effects and Fatalities Associated With Subcutaneous Allergen Immunotherapy","volume":"18","author":"Bukantz","year":"2004","journal-title":"Clin Allergy Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2012.12.014","article-title":"Perception and Practice of Sublingual Immunotherapy Among Practicing Allergists in the United States: A Follow-Up Survey","volume":"110","author":"Sikora","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1398-9995.2009.02309.x","article-title":"Sub-Lingual Immunotherapy: World Allergy Organization Position Paper 2009","volume":"64","author":"Canonica","year":"2009","journal-title":"Allergy"},{"key":"B11","article-title":"Sublingual Immunotherapy: Certainties, Unmet Needs and Future Directions","volume":"41","author":"Passalacqua","year":"2009","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.iac.2015.08.005","article-title":"Subcutaneous Immunotherapy and Sublingual Immunotherapy: Comparative Efficacy, Current and Potential Indications, and Warni\u2013s\u2013United States Versus Europe","volume":"36","author":"Nelson","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.03.013","article-title":"Real-Life Compliance and Persistence Among Users of Subcutaneous and Sublingual Allergen Immunotherapy","volume":"132","author":"Kiel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/all.12600","article-title":"Determinants of Efficacy and Safety in Epicutaneous Allergen Immunotherapy: Summary of Three Clinical Trials","volume":"70","author":"Senti","year":"2015","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12931-016-0324-9","article-title":"Intralymphatic Immunotherapy of Pollen-Induced Rhinoconjunctivitis: A Double-Blind, Placebo-Controlled Trial","volume":"17","author":"Hylander","year":"2016","journal-title":"Respir Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/all.12513","article-title":"A High Polymerized Grass Pollen Extract Is Efficacious and Safe in a Randomized Doubleblind, Placebo-Controlled Study Using a Novel Up-Dosing Cluster-Protocol","volume":"69","author":"Klimek","year":"2014","journal-title":"Allergy"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/all.12148","article-title":"Double-Blind, Placebo-Controlled, Dose-Ranging Study of New Recombinant Hypoallergenic Bet V 1 in an Environmental Exposure Chamber","volume":"68","author":"Meyer","year":"2013","journal-title":"Allergy"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12488","article-title":"Fel D 1-Derived Synthetic Peptide Immuno-Regulatory Epitopes Show a Long-Term Treatment Effect in Cat Allergic Subjects","volume":"45","author":"Couroux","year":"2015","journal-title":"Clin Exp Allergy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.12.1561","article-title":"The Novel TLR-9 Agonist QbG10 Shows Clinical Efficacy in Persistent Allergic Asthma","volume":"131","author":"Beeh","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":":121","DOI":"10.1016\/j.jaci.2013.05.032","article-title":"Efficacy of a Short Course of Specific Immunotherapy in Patients With Allergic Rhinoconjunctivitis to Ragweed Pollen","volume":"133","author":"Patel","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2015.08.009","article-title":"The Use of Adjuvants for Enhancing Allergen Immunotherapy Efficacy","volume":"36","author":"Chesn\u00e9","year":"2016","journal-title":"Immunol Allergy Clin North Am"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0b013e32835a11d6","article-title":"Adjuvants for Immunotherapy","volume":"12","author":"Pfaar","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24631","article-title":"Pollinex Quattro: An Innovative Four Injections Immunotherapy in Allergic Rhinitis","volume":"9","author":"Rosewich","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"B24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.33619\/2414-2948\/63\/01","article-title":"Pollen Pollution Strategy of Artemisia and Chenopodiaceae","volume":"7","author":"Kobzar","year":"2021","journal-title":"Bull Sci Pract"},{"key":"B25","first-page":"313","article-title":"Estivo-Autumnal Pollinosis","volume":"12","author":"Cornillon","year":"1972","journal-title":"Rev Fr Allergol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2008.10.012","article-title":"Immune Recognition of Novel Isoforms and Domains of the Mugwort Pollen Major Allergen Art V 1","volume":"46","author":"Dedic","year":"2009","journal-title":"Mol Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1495","article-title":"Native Art V 1 and Recombinant Art V 1 Are Able to Induce Humoral and T Cell-Mediated In Vitro and In Vivo Responses in Mugwort Allergy","volume":"111","author":"Schmid-Grendelmeier","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"108611","DOI":"10.1016\/j.vetmic.2020.108611","article-title":"Poly(I:C) Augments Inactivated Influenza Virus-Chitosan Nanovaccine Induced Cell Mediated Immune Response in Pigs Vaccinated Intranasally","volume":"242","author":"Renu","year":"2020","journal-title":"Vet Microbiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"116434","DOI":"10.1016\/j.carbpol.2020.116434","article-title":"Chitosan-Adjuvanted Salmonella Subunit Nanoparticle Vaccine for Poultry Delivered Through Drinking Water and Feed","volume":"243","author":"Renu","year":"2020","journal-title":"Carbohydr Polym"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2013.10.044","article-title":"Mannose-Conjugated Chitosan Nanoparticles Loaded With Rifampicin for the Treatment of Visceral Leishmaniasis","volume":"101","author":"Chaubey","year":"2014","journal-title":"Carbohydr Polym"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1177\/0192623312438738","article-title":"International Harmonization of Toxicologic Pathology Nomenclature: An Overview and Review of Basic Principles","volume":"40","author":"Mann","year":"2012","journal-title":"Toxicol Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/01926230252824761","article-title":"Qualitative and Quantitative Analysis of Nonneoplastic Lesions in Toxicology Studies","volume":"30","author":"Shackelford","year":"2002","journal-title":"Toxicol Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2005.02287.x","article-title":"Vaccinations With T-Helper Type 1 Directing Adjuvants Have Different Suppressive Effects on the Development of Allergen-Induced T-Helper Type 2 Responses","volume":"35","author":"Trujillo-Vargas","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1710-1492-10-4","article-title":"Aluminium Adjuvants and Adverse Events in Subcutaneous Allergy Immunotherapy","volume":"10","author":"Exley","year":"2014","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.05.063","article-title":"Aluminium in Allergen-Specific Subcutaneous Immunotherapy\u2013 A German Perspective","volume":"32","author":"Kramer","year":"2014","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.009","article-title":"Randomized Clinical Trial of Immunogenicity and Safety of a Recombinant H1N1\/2009 Pandemic Influenza Vaccine Containing Advax Polysaccharide Adjuvant","volume":"30","author":"Gordon","year":"2012","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.09.034","article-title":"Immunogenicity and Safety of Advax, A Novel Polysaccharide Adjuvant Based on Delta Inulin, When Formulated With Hepatitis B Surface Antigen: A Randomized Controlled Phase 1 Study","volume":"32","author":"Gordon","year":"2014","journal-title":"Vaccine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.021","article-title":"Advax, A Polysaccharide Adjuvant Derived From Delta Inulin, Provides Improved Influenza Vaccine Protection Through Broad-Based Enhancement of Adaptive Immune Responses","volume":"30","author":"Honda-Okubo","year":"2012","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jpba.2019.04.017","article-title":"Pharmaceutical and Preclinical Evaluation of Advax Adjuvant as a Dose-Sparing Strategy for Ant Venom Immunotherapy","volume":"172","author":"Wanandy","year":"2019","journal-title":"J Pharm BioMed Anal"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.03.035","article-title":"Randomized Controlled Trial Demonstrating the Benefits of Delta Inulin Adjuvanted Immunotherapy in Patients With Bee Venom Allergy","author":"Heddle","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1368598","article-title":"Advax4 Delta Inulin Combination Adjuvant Together With ECMX, a Fusion Construct of Four Protective mTB Antigens, Induces a Potent Th1 Immune Response and Protects Mice Against Mycobacterium Tuberculosis Infection","volume":"13","author":"de Paula Oliveira Santos","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B42","doi-asserted-by":"publisher","first-page":"8582","DOI":"10.1038\/s41598-017-09119-y","article-title":"Delta Inulin-Based Adjuvants Promote the Generation of Polyfunctional CD4+ T Cell Responses and Protection Against Mycobacterium Tuberculosis Infection","volume":"7","author":"Counoupas","year":"2017","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"28912","DOI":"10.1038\/srep28912","article-title":"Alzheimer's Disease Advax(CpG)- Adjuvanted MultiTEP-Based Dual and Single Vaccines Induce High-Titer Antibodies Against Various Forms of Tau and A\u03b2 Pathological Molecules","volume":"6","author":"Davtyan","year":"2016","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of Ferrets and Mice With Recombinant SARS-CoV-2 Spike Protein Formulated With Advax-SM Adjuvant Protects Against COVID-19 Infection","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-2659.2008.00059.x","article-title":"MF59-Adjuvanted Vaccines for Seasonal and Pandemic Influenza Prophylaxis","volume":"2","author":"Banzhoff","year":"2008","journal-title":"Influenza Other Respir Viruses."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01760","article-title":"AS03- and MF59-Adjuvanted Influenza Vaccines in Children","volume":"8","author":"Wilkins","year":"2017","journal-title":"Front Immunol"},{"key":"B47","first-page":"24","article-title":"An Adjuvanted Subunit SARS-CoV-2 Spike Protein Vaccine Provides Protection Against Covid-19 Infection and Transmission","volume-title":"NPJ Vaccines","author":"Tabynov","year":"2022"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21523","article-title":"Vaccine Adjuvants: Current Challenges and Future Approaches","volume":"98","author":"Wilson-Welder","year":"2009","journal-title":"J Pharm Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: A New Generation of Water in Oil Emulsions as Adjuvants for Human Vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expert Rev Vaccines"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2013.811188","article-title":"An Update on Safety and Immunogenicity of Vaccines Containing Emulsion-Based Adjuvants","volume":"12","author":"Fox","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B51","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10875-011-9632-5","article-title":"Safety and Immunogenicity of Multimeric-0\u20131 - A Novel Universal Influenza Vaccine","volume":"32","author":"Atsmon","year":"2012","journal-title":"J Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.089","article-title":"Synthetic Influenza Vaccine (FLU-V) Stimulates Cell Mediated Immunity in a Double-Blind, Randomized, Placebo-Controlled Phase I Trial","volume":"30","author":"Pleguezuelos","year":"2012","journal-title":"Vaccine"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2014.931936","article-title":"Intranasal Formulations: Promising Strategy to Deliver Vaccines","volume":"11","author":"Riese","year":"2014","journal-title":"Exp Opin Drug Deliv"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02224","article-title":"Nanoparticle Vaccines Against Infectious Diseases","volume":"9","author":"Pati","year":"2018","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.10.5165","article-title":"The Toll-Like Receptor 5 Stimulus Bacterial Flagellin Induces Maturation and Chemokine Production in Human Dendritic Cells","volume":"170","author":"Means","year":"2003","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S238445","article-title":"Oral Deliverable Mucoadhesive Chitosan Salmonella Subunit Nanovaccine for Layer Chickens","volume":"15","author":"Renu","year":"2020","journal-title":"Int J Nanomed"},{"key":"B57","doi-asserted-by":"publisher","first-page":"869718","DOI":"10.1155\/2013\/869718","article-title":"Targeting Antigens to Dendritic Cell Receptors for Vaccine Development","volume":"2013","author":"Apostolopoulos","year":"2013","journal-title":"J Drug Deliv"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00934","article-title":"Mucosal Immunity and Protective Efficacy of Intranasal Inactivated Influenza Vaccine Is Improved by Chitosan Nanoparticle Delivery in Pigs","volume":"9","author":"Dhakal","year":"2018","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/vaccines8020299","article-title":"Mannose-Modified Chitosan-Nanoparticle-Based Salmonella Subunit OralVaccine-Induced Immune Response and Efficacy in a Challenge Trial in Broilers","volume":"8","author":"Han","year":"2020","journal-title":"Vaccines"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-125","article-title":"Role of Tnf\u03b1 in Pulmonary Pathophysiology","volume":"7","author":"Mukhopadhyay","year":"2006","journal-title":"Respir Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4373","article-title":"Resolution of Inflammation by Interleukin-9-Producing Type 2 Innate Lymphoid Cells","volume":"23","author":"Rauber","year":"2017","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"202e208","DOI":"10.1136\/thx.2005.052399","article-title":"Evaluation of Airway Inflammation by Quantitative Th1\/Th2 Cytokine mRNA Measurement in Sputum of Asthma Patients","volume":"61","author":"Truyen","year":"2006","journal-title":"Thorax"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-07911-0_10","article-title":"IgA, IgA Receptors, and Their Anti-Inflammatory Properties","volume":"382","author":"Mkaddem","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575936","article-title":"Mimicking Antigen-Driven Asthma in Rodent Models-How Close Can We Get","volume":"11","author":"Alessandrini","year":"2020","journal-title":"Front Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/all.12642","article-title":"Pollen-Derived Adenosine Is a Necessary Cofactor for Ragweed Allergy","volume":"70","author":"Wimmer","year":"2015","journal-title":"Allergy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.828690\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T08:48:03Z","timestamp":1647334083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.828690\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2022.828690"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.828690","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"article-number":"828690"}}